Critical access hospitals, rural referral centers, sole community hospitals, and free-standing cancer hospitals will not be getting access to voluntary 340B pricing on Bristol Myers Squibb’s (BMS) expensive myeloma drugs—a development certain to be a disappointment for rural providers.
Earlier this month, BMS announced that hospitals would face significant restrictions on access to 340B discounts in the contract pharmacy setting. At the same time, BMS said it would let covered entities excluded from its limited distribution network for Revlimid, Pomalyst, and Thalomid begin to receive 340B pricing on the drugs.
Critical access hospitals, rural referral centers, sole community hospitals, and free-standing cancer hospitals will not be getting access to voluntary 340B pricing on Bristol Myers Squibb’s (BMS) expensive myeloma drugs—a development certain to be a disappointment for rural providers.
Please Login or Become a Paid Subscriber to View this Content
If you are already a paid subscriber, please follow the steps below.
